Avicanna Inc's latest earnings report has raised eyebrows among investors as the company continues to navigate the challenging landscape of the pharmaceutical sector.
On August 13, 2026, Avicanna Inc (AVCN.TO) released its earnings report for the fiscal period ending June 30, 2026, revealing an EPS of -0.0081. This marks a continuation of a trend of negative earnings, raising questions about the company's financial health and future prospects.
Recent earnings trend
Advertisement
Avicanna Inc
AVCN.TO
AVCN.TO
Avicanna Inc
WealthAwesomeMarket cap
$16.35M
52W high
$0.30
52W low
$0.10
1W change
-3.85%
Beta
0.33
Analyst Price Targets
Based on analyst covering AVCN
Wall Street analysts forecast AVCN stock price to rise 460.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+460.0% Upside
Current Price
C$0.13
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCN's historical volatility
30-Day Vol
66.1%
Annualized
90-Day Vol
65.9%
Annualized
Trend (90d)
-16.5%
Annualized drift
90d Mean
C$0.12
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.12 | C$0.10 – C$0.15 |
| 60 trading days | C$0.12 | C$0.09 – C$0.17 |
| 90 trading days | C$0.12 | C$0.08 – C$0.17 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | -0.0081 | — | — |
| 2026-03-31 | 2026-05-13 | -0.0078 | — | — |
| 2025-09-30 | 2025-11-13 | -0.0116 | — | — |
| 2025-06-30 | 2025-08-14 | -0.0070 | — | — |
| 2025-03-31 | 2025-05-14 | 0.0004 | — | — |
| 2024-09-30 | 2024-11-14 | -0.0087 | — | — |
Advertisement
Investor takeaway: Canadian investors should closely monitor Avicanna's performance, especially given its history of missing EPS estimates. With a market cap of approximately CA$16.35 million and a significant gap between its current price and analyst price targets, the stock remains a speculative play in the health care sector.
EPS of -0.0081 Signals Ongoing Challenges
Avicanna has not recorded a single earnings surprise in its last four quarters, reflecting ongoing struggles to achieve profitability in a competitive pharmaceutical landscape.
Bull case
Avicanna is focusing on expanding its medical cannabis portfolio, including the recent launch of the QUIX™ rapid-onset products. This positions the company well to meet the growing demand for cannabinoid-based treatments.
Bear case
The ongoing negative earnings and lack of recent positive surprises may deter potential investors. With a history of missing earnings estimates and a low profit margin of -12.09%, the company's financial stability is in question.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
